BioCardia (BCDA)
(Delayed Data from NSDQ)
$0.38 USD
+0.01 (2.34%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.39 +0.01 (3.56%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BCDA 0.38 +0.01(2.34%)
Will BCDA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BCDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCDA
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates
BCDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioCardia (BCDA) Up on Plans for Second Heart Failure Study
BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study
BioCardia, Inc. (BCDA) Reports Q2 Loss, Lags Revenue Estimates
Other News for BCDA
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort
BioCardia completes enrollment of CardiAMP cell therapy trial
Expensify And 2 Other Stocks Under $2 Insiders Are Buying
12 Health Care Stocks Moving In Friday's Pre-Market Session
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results